PT  - JOURNAL ARTICLE
AU  - Anne Grete Semb
AU  - Silvia Rollefstad
AU  - Eirik Ikdahl
AU  - Grunde Wibetoe
AU  - Joseph Sexton
AU  - Cindy Crowson
AU  - Piet van Riel
AU  - George Kitas
AU  - Ian Graham
AU  - Solbritt Rantapää-Dahlqvist
AU  - George Athanasios Karpouzas
AU  - Elena Myasoedova
AU  - Miguel A Gonzalez-Gay
AU  - Petros P Sfikakis
AU  - Maria G Tektonidou
AU  - Argyro Lazarini
AU  - Dimitrios Vassilopoulos
AU  - Bindee Kuriya
AU  - Carol Hitchon
AU  - Maria Simona Stoenoiu
AU  - Patrick Durez
AU  - Virginia Pascual-Ramos
AU  - Dionicio Angel Galarza-Delgado
AU  - Pompilio Faggiano
AU  - Durga Prasanna Misra
AU  - Andrew A Borg
AU  - Rong Mu
AU  - Erkin M Mirrakhimov
AU  - Diane Gheta
AU  - Karen Douglas
AU  - Vikas Agarwal
AU  - Svetlana Myasoedova
AU  - Lev Krougly
AU  - Tatiana Valentinovna Popkova
AU  - Alena Tuchyňová
AU  - Michal Tomcik
AU  - Michal Vrablik
AU  - Jiri Lastuvka
AU  - Pavel Horak
AU  - Helena Kaspar Medkova
AU  - Anne M Kerola
ED  - ,
TI  - Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
AID  - 10.1136/rmdopen-2021-001724
DP  - 2021 Jul 01
TA  - RMD Open
PG  - e001724
VI  - 7
IP  - 2
4099  - http://rmdopen.bmj.com/content/7/2/e001724.short
4100  - http://rmdopen.bmj.com/content/7/2/e001724.full
SO  - RMD Open2021 Jul 01; 7
AB  - Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention.Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014–2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM.Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM.Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .No data are available. All data relevant to the study are included in the article or uploaded as supplementary information. The data were pseudonymised by each centre before transferred to the data handling centre at Diakonhjemmet hospital, where it is stored on a central server. The data handling manager is Joe Sexton (joesexton0@gmail.com) and the data centre leader is Anne Grete Semb (a-semb@diakonsyk.no).